Endoscopic versus percutaneous management for symptomatic pancreatic fluid collections: a systematic review and meta-analysis

Authors
Muhammad Ali Khan¹, Tariq Hammad², Zubair Khan³, Wade Lee⁴, Monica Gaidhane⁵, Amy Tyberg⁵, Michel Kahaleh³

Institutions
1 Division of Gastroenterology, University of Tennessee Health Science Center, Memphis, TN, USA
2 Division of Gastroenterology, Baylor College of Medicine, Houston, TX, USA
3 Division of Gastroenterology, University of Toledo, Toledo, OH, USA
4 Mulford and Carlson Libraries, University of Toledo, Toledo, OH, USA
5 Department of Medicine – Rutgers Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, Robert Wood Johnson University Hospital

submitted 5.12.2017
accepted after revision 25.1.2018

Bibliography
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 2364-3722

Corresponding author
Michel Kahaleh, MD, AGAF, FACP, FASGE, Professor of Medicine, Clinical Director of Gastroenterology, Chief of Endoscopy, Director Pancreas Program, Department of Medicine – Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Robert Wood Johnson University Hospital, 1 RWJ Place, MEB 464, New Brunswick, NJ 08901, USA
Fax: 732-235-5537
mkahaleh@gmail.com

ABSTRACT

Background Symptomatic pancreatic fluid collections (PFCs) are managed by surgical, percutaneous, or endoscopic drainage. Due to morbidity associated with surgical drainage, percutaneous and/or endoscopic options have increasingly been used as initial management.

Aims We conducted a systematic review and meta-analysis comparing the efficacy and safety of endoscopic versus percutaneous drainage for management of PFCs.

Methods We searched several databases from inception through 31 August 2017 to identify comparative studies using endoscopic or percutaneous drainage for PFCs. Our primary outcome was clinical success. Secondary outcomes were technical success, adverse events (AE), rates of recurrence, requirement for subsequent procedures, and length of stay in hospital. Pooled risk ratios (RR) and mean difference (MD) were calculated for categorical and continuous outcomes, respectively.

Results Seven studies with 490 patients were included in the final analysis. Pooled RR for clinical success was 0.40 (0.26, 0.61), I² = 42% in favor of endoscopic management. On sensitivity analysis, after excluding one study on patients with walled-off necrosis (WON), the clinical success was 0.43 (0.28, 0.66) with no heterogeneity. Pooled RR for technical success was 1.50 (0.52, 4.37) with no heterogeneity. Pooled RR for AE and rate of recurrence were 0.77 (0.46, 1.28) and 0.60 (0.29, 1.24), respectively. Pooled MD for length of stay in hospital and rate of re-intervention were −8.97 (−12.88, −5.07) and −0.66 (−0.93, −0.38), respectively, in favor of endoscopic drainage.

Conclusions Endoscopic drainage should be the preferred therapeutic modality for PFCs compared to percutaneous drainage as it is associated with significantly better clinical success, a lower re-intervention rate, and a shorter hospital length of stay.

Introduction

Acute pancreatitis is the most common gastroenterological cause for inpatient admission in the United States and subsequently results in substantial morbidity, mortality, and cost
burdens [1]. Pancreatic fluid collections (PFCs) are common complications of pancreatitis and may occur in up to 20% of necrotizing pancreatitis [2, 3]. Based on the acuity and content, PFCs are classified according to the revised Atlanta classification into four distinctive categories: acute peripancreatic fluid collection (APFC), acute necrotic collections (ANC), pancreatic pseudocysts (PPs) and walled-off necrosis (WON) [4]. Additionally, about 15% to 30% of patients undergoing distal pancreatic resections develop postoperative PFCs due to pancreatic duct leaks [5 – 7].

Drainage of PFCs is indicated if they become infected or symptomatic. This can be performed by surgical, percutaneous, or endoscopic approaches. Surgical drainage, both open and minimally invasive retroperitoneal necrosectomy, has been associated with high rates of morbidity and mortality with a 47% to 72% complication rate [8 – 10]. Endoscopic drainage (ED) and percutaneous drainage (PD) have widely replaced surgical drainage as initial, efficacious, and less invasive approaches for symptomatic PFCs. Despite having comparable clinical efficacy, in some studies PD was associated with a higher rate of fistula formation, a higher rate of re-interventions, a longer length of hospital stay, and a higher median number of follow-up abdominal imaging studies compared to ED [11, 12].

Over the past two decades, advances in endoscopic techniques have made ED the preferred drainage modality. The use of endoscopic ultrasound (EUS) allows for assessment of the collection, creation of an internal fistulous tract even into collections not bulging into the gastrointestinal lumen, avoidance of intervening vasculature, and deployment of internal drainage stents. Direct endoscopic necrosectomy (DEN) is a rapidly evolving technique in which endoscopic debridement of the PFC (WON in particular) is performed through the cyst-gastrostomy or cyst-duodenostomy stent [13]. Several types of stent have been used for ED: plastic double pigtail stents, fully covered self-expanding metal stents (FCSEMS) and more recently, luminal apposing metal stents (LAMS). LAMS have made DEN easier, more efficient, and with no difference in cost compared to plastic stent usage [14, 15].

Few studies have compared PD with ED for management of symptomatic PFC. The aim of the present systematic review and meta-analysis is to compare the efficacy (technical success and clinical success) and safety (adverse events and rate of recurrence) of endoscopic versus percutaneous drainage for management of PFCs based on the information available as of August 2017.

Methods
Identification and retrieval of primary studies
The systematic review and meta-analysis was conducted according to the guidelines of preferred reporting items for systematic reviews and meta-analyses (PRISMA) [16]. The search strategy and subsequent literature search were developed in consultation with an experienced medical reference librarian (WML). The search strategies were developed in Medline and then replicated using the same subject headings and keywords for Cochrane database, EMBASE, and Web of Science from inception through 31 August 2017. Search terms included: “pancreatic fluid collections”, “pancreatic pseudocyst”, “walled off necrosis”, “percutaneous drainage”, and “endoscopic drainage”. The search accounted for plurals and variations in spelling with the use of appropriate wildcards. There was no restriction of language. The full search strategy is available as Appendix 1.

Articles were selected for full text review on the basis of their title and abstract. To increase the yield of our search strategy, we manually searched references and related citations then cross-referencing was performed for articles identified. All results were downloaded into EndNote 7.5 (Thompson ISI ResearchSoft, Philadelphia, Pennsylvania, United States), a bibliographic database manager; any duplicate citation was identified and removed.

Study selection, data extraction, and quality assessment
Eligibility criteria were determined a priori by two study authors (MAK and MK) and included comparative studies using endoscopic or percutaneous drainage for symptomatic PFC. Endoscopic drainage could be achieved by transmural and/or transpapillary route, with or without the use of endoscopic ultrasound (EUS).

Studies were included only if they reported clinical success (clinical and radiological resolution) and post-procedure adverse events. Abstracts were excluded only if data presented initially were later published as a full peer reviewed journal article, in which case the fully published study was included. Corresponding authors of studies were contacted when required data from studies was not available or there was concern for overlap of patients among studies. Abstracts of Digestive Disease Week were searched manually from year 2012 up to 2017 for any comparative studies. Two independent reviewers (TH and MAK) reviewed the title and abstract search with inclusion decisions for each study made independently based on the eligibility criteria. Any disagreement between reviewers was discussed with a third reviewer (MK) and agreement was reached by consensus.

Data from included studies were independently extracted by two reviewers (ZK and MAK). Extracted data included study design, country, year of publication, patient demographics, type of PFC, etiology of the PFC, site and size of the PFC, DEN, drainage approach, clinical success, technical success, rate of recurrence, length of stay in hospital, and adverse events. After complete extraction of data, the data sheets were compared and any disagreement between reviewers was to be discussed with a third reviewer (MK) with agreement reached by consensus.

Quality of studies was assessed independently by two investigators (MAK and ZK) using the Newcastle Ottawa scale (NOS) for observational studies [17]. Any discrepancy in quality assessment between reviewers was discussed with a third reviewer (MK) with agreement reached by consensus.

Data synthesis and statistical analysis
All statistical analyses were conducted using Review Manager (RevMan, version 5.3 for Windows; The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) and
Comprehensive Meta-analysis (version 3.0; Englewood, NJ, United States). The primary outcome was clinical success (clinical and radiological resolution). Secondary outcomes were technical success, adverse events (AE), rates of recurrence, requirement for subsequent procedures, and length of stay in hospital. Pooled risk ratios (RR) and mean difference (MD) were calculated for categorical and continuous outcomes, respectively, and analyzed using a fixed effect model, unless heterogeneity was encountered, in which case we used a random effects model. When studies included zero events in both arms, continuity correction was applied to include the zero-event study in the pooled estimate [18, 19]. To assess heterogeneity, we used $I^2$ statistics and Cochran’s Q test, in which a $p$ value <0.1 for Cochran’s Q test indicated the presence of heterogeneity. The $I^2$ values of >50% were consistent with significant heterogeneity [20]. We expected heterogeneity in our estimate as various etiologies of PFCs were included. Therefore, a sensitivity analysis was conducted after excluding study comparing performance in WON. We also conducted a subgroup analysis based on type of endoscopic drainage, i.e. EUS-guided transmural drainage exclusively and endoscopic drainage including both transmural and/or transpapillary methods. We assessed publication bias with funnel plots and Egger’s test if deemed necessary.

Results

The search strategy identified 3892 citations of which 1145 were removed as duplicates. Out of the remaining 2747 articles, 2584 were removed after title and abstract review. Bibliographic search of 163 articles did not reveal any additional study. Therefore, a total of 163 articles were reviewed of which 7 observational studies [10, 11, 21–25] with 490 patients were included in this systematic review and meta-analysis. An abstract [26], initially presented at Digestive Disease Week 2012, was excluded as results from this study were incorporated into a single center study published in 2014 [11]. The search strategy is highlighted in Fig. 1.

Study characteristics and quality assessment

All seven studies [10, 11, 21–25] were retrospective observational studies. Among 490 patients, 242 underwent endoscopic drainage while the remaining 248 underwent percutaneous drain placement. Three studies [21, 22, 25] exclusively evaluated PFCs after pancreatic surgery (n = 189), two studies [11, 24] were comprised of PP patients only (n = 112), one study [10] focused on WON patients only (n = 24), and the remaining one study [23] included both WON and PP. In patients who underwent endoscopic management, two studies [21, 23] used both plastic and metal stents at the discretion of the endoscopist, four studies [10, 11, 22, 24] used plastic stents exclusively, and one study did not mention the type of stents used [25]. Patient demographics are highlighted in Table 1. Two studies [10, 22] exclusively used EUS for endoscopic management with the use of one to three (7–10 Fr) pigtail plastic stents. In the remaining studies, EUS was used at the discretion of the endoscopist.

Quality assessment of studies was conducted using NOS assessment tool. All seven studies were rated as moderate quality studies. This tool assesses quality in three parameters of selection, comparability, and exposure/outcome, and allocates a maximum of 4, 2, and 3 points, respectively. High quality studies are scored greater than 7 on this scale, and moderate quality studies, between 5 and 7. Detailed quality assessment is presented in Table 2.

Meta-analysis

Our primary outcome of interest was clinical success which was defined as radiological resolution of PFC, along with improvement in clinical symptoms leading to subsequent removal of drains and stents. All seven studies [10, 11, 21–25] presented data on clinical success. Pooled RR with 95% confidence interval (CI) was 0.40 (0.26, 0.61), Cochran’s Q test $p$ = 0.11, $I^2$ = 42% (Fig. 2). Funnel plot appeared asymmetric but Egger’s test failed to detect any publication bias (intercept = 0.14, $p$ = 0.91, two-tailed). On sensitivity analysis, after excluding the study with WON, pooled RR with 95% CI was 0.43 (0.28, 0.66), Cochran’s Q test $p$ = 0.13, $I^2$ = 41%. On subgroup analysis,
<table>
<thead>
<tr>
<th>Study, year and country</th>
<th>Design</th>
<th>Comparison groups</th>
<th>Number of patients</th>
<th>Age, years</th>
<th>Males</th>
<th>Size of PFC, cm</th>
<th>Technical success</th>
<th>Clinical success</th>
<th>Recurrence</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson et al., 2009, USA [24]</td>
<td>Retrospective</td>
<td>ED</td>
<td>24</td>
<td>49</td>
<td>NR</td>
<td>9.5</td>
<td>22</td>
<td>21</td>
<td>0</td>
<td>2 bleeding, 1 enterocutaneous fistula, 1 pancreatic fistula</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PD</td>
<td>7</td>
<td>52</td>
<td>NR</td>
<td>9.1</td>
<td>7</td>
<td>5</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Azeem et al., 2012, USA [21]</td>
<td>Retrospective</td>
<td>ED</td>
<td>15</td>
<td>53</td>
<td>8</td>
<td>7</td>
<td>15</td>
<td>12</td>
<td>2</td>
<td>1 bleeding, 1 stent migration into PFC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PD</td>
<td>33</td>
<td>53</td>
<td>14</td>
<td>6.4</td>
<td>31</td>
<td>26</td>
<td>6</td>
<td>2 bleeding, 1 acute pancreatitis</td>
</tr>
<tr>
<td>Kwon et al., 2013, USA [22]</td>
<td>Retrospective</td>
<td>ED</td>
<td>12</td>
<td>62.1</td>
<td>4</td>
<td>8.9</td>
<td>12</td>
<td>12</td>
<td>0</td>
<td>1 bleeding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PD</td>
<td>14</td>
<td>55.6</td>
<td>5</td>
<td>10</td>
<td>14</td>
<td>11</td>
<td>3</td>
<td>2 cysto-cutaneous fistula, 1 pleural effusion, 1 bleeding, 1 severe pain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PD</td>
<td>40</td>
<td>52</td>
<td>26</td>
<td>9.4</td>
<td>39</td>
<td>29</td>
<td>NR</td>
<td>5 pseudocyst infection, 1 bleeding</td>
</tr>
<tr>
<td>Kumar et al., 2014, USA [10]</td>
<td>Retrospective</td>
<td>ED</td>
<td>12</td>
<td>58</td>
<td>8</td>
<td>NR</td>
<td>NR</td>
<td>11</td>
<td>NR</td>
<td>1 bleeding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PD</td>
<td>12</td>
<td>53</td>
<td>9</td>
<td>NR</td>
<td>NR</td>
<td>3</td>
<td>NR</td>
<td>1 wound infection, 1 death</td>
</tr>
<tr>
<td>Keane et al., 2016, UK [23]</td>
<td>Retrospective</td>
<td>ED</td>
<td>109</td>
<td>55</td>
<td>60</td>
<td>10.3</td>
<td>100</td>
<td>89</td>
<td>8</td>
<td>4 stent migration, 3 pneumoperitoneum, 2 bleeding, 2 esophageal perforation, 1 pneumonia, 1 pneumothorax</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PD</td>
<td>55</td>
<td>50</td>
<td>37</td>
<td>10.2</td>
<td>54</td>
<td>30</td>
<td>2</td>
<td>4 deaths, 2 pancreatic fistula</td>
</tr>
<tr>
<td>Ngamruengphong et al., 2017, USA [25]</td>
<td>Retrospective</td>
<td>ED</td>
<td>28</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>28</td>
<td>27</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PD</td>
<td>87</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>75</td>
<td>71</td>
<td>20</td>
<td>7</td>
</tr>
</tbody>
</table>

ED, endoscopic drainage; PD, percutaneous drainage; PFC, pancreatic fluid collection; NR, not recorded.
pooled RR in EUS guided transmural drainage exclusively and endoscopic transmural and/or transpapillary drainage were 0.13 (0.03, 0.61), $P = 0.0$% and 0.44 (0.28, 0.68), $P = 51$%, respectively (Fig. 2). Technical success was defined as completion of index procedure with successful stent or drain placement in the intended position as determined endoscopically or radiologically. Six studies [11, 21–25] with 466 patients compared technical success. Pooled RR was 1.50 (0.52, 4.37), Cochran’s Q test $P = 0.34$, $I^2 = 12$% (Fig. 3). No publication bias was detected with funnel plot and Egger’s test of asymmetry (intercept 5.21, $P = 0.67$, two-tailed). Although we did not find any difference in technical success, clinical success was significantly better in the endoscopic drainage group. This was consistent, even after exclusion of the study evaluating WON exclusively.

Adverse events were defined as post procedure complications which required any additional intervention or resulted in hospital stay. All seven studies reported data on adverse events. Pooled RR for overall adverse events was 0.77 (0.46, 1.28), Cochran’s Q test $P = 0.75$, $I^2 = 0$% (Fig. 4). No publication bias was detected with funnel plot and Egger’s test (intercept $= -1.56$, $P = 0.09$, two-tailed). On subgroup analysis, pooled RR for exclusive EUS guided transmural drainage and endoscopic transmural and/or transpapillary drainage were 0.33 (0.07, 1.46), $I^2 = 0$% and 0.86 (0.50, 1.49), $P = 0$%, respectively. Bleeding was the most common adverse event, occurring in 4% of patients in the endoscopic group and 1.5% in the percutaneous group. However, this difference was not statistically significant ($P = 0.10$). Five deaths occurred during 30-day follow-up in the percutaneous group, while no deaths occurred in the endoscopic group. Once again, this difference was not statistically significant ($P = 0.16$). Recurrence was defined as reoccurrence of the collection after removal of the drain or stent. Five studies [21–25] evaluated recurrence rate with both procedures. Pooled RR was 0.60 (0.29, 1.24), Cochran’s Q test $P = 0.22$, $I^2 = 30$% (Fig. 5). Three studies [10, 23, 25] provided data on requirement for re-interventions; pooled mean difference was $-0.66$ (−0.93, −0.38). Cochran’s Q test $P = 0.01$, $I^2 = 77$% (Fig. 6a). Finally, length of stay in days was compared in three studies; pooled mean difference with 95%CI was $-8.97$ (−12.88, −5.07). Cochran’s Q test $P = 0.13$, $I^2 = 51$% (Fig. 6b).

Discussion

Due to the invasive nature and morbidity associated with surgical drainage of symptomatic PFCs, percutaneous and/or endoscopic options have increasingly been used as initial management. Percutaneous drainage can be performed under local anesthesia avoiding the need for monitored or general anesthesia; however, percutaneous drainage requires an external catheter which compromises patients’ quality of life, requiring daily care and maintenance and may result in localized skin irritation. Endoscopic drainage allows for larger diameter internal stent placement, avoiding the need for external drains, allowing for DEN, and allowing for reintroduction of pancreatic fluid back into the gastrointestinal tract which is more physiological compared to percutaneous drainage where pancreatic fluid is lost. However, it requires general anesthesia to be performed safely. While both are efficacious in published studies, one has not been definitively identified as superior to the other, justifying...
the need for a comprehensive systematic review and meta-analysis. This systematic review of observational studies suggests that endoscopic drainage of PFCs should be the preferred option for management compared to percutaneous drainage because it was associated with better clinical success, a lower requirement for re-interventions, and a shorter length of stay in hospital.

When comparing the efficacy of endoscopic with percutaneous drainage for management of PFCs, we found no difference in technical success with no heterogeneity across studies. However, despite similar technical success, clinical success was found to be significantly higher in the endoscopic drainage group. Our initial analysis had moderate heterogeneity which was expected as we had included various types of PFCs. We were able to explore this heterogeneity with a sensitivity analysis after excluding one study [10] evaluating both procedures in the management of WON exclusively. Our results of better clinical success with endoscopic drainage remained consistent even after this sensitivity analysis and may have clinical implications for the management of PFCs. Furthermore, endoscopic creation of a cyst-gastrostomy or cyst-duodenostomy reintroduces pancreatic fluid back into the gastrointestinal tract and
is more physiological compared with pancreatic fluid losses with percutaneous drainage. Finally, percutaneous drainage has an external catheter which compromises patients’ quality of life, requiring daily care and maintenance and which may result in localized skin irritation.

WON deserves special consideration as such patients have necrosis of pancreatic parenchyma leading to debris in the fluid collection and may not be easily managed by a single drain. Kumar et al. [10] found only 25% clinical success in the percutaneous drainage group while managing WON. Endoscopic transmural drainage has the advantage in such a scenario because it provides the endoscopist with the ability to perform DEN with mechanical removal of necrotic debris, which cannot be done with small bore percutaneous drains. Although not used by any of the studies included in this meta-analysis, LAMS have a reported clinical success rate of 90% for management of WON [27].

We did not find any significant difference in post procedure adverse events and rate of recurrence of PFCs between ED and PD. Amongst individual adverse events, we found the rate of bleeding to be higher in the endoscopic group (4%) compared to the percutaneous group (1.5%), but this difference was not statistically significant ($P = 0.1$). Bleeding is encountered with endoscopic transmural drainage when there is intervening vas-
At the site of cyst-gastrostomy. However, this complication may decrease with the increasing use of EUS which allows high resolution, real time imaging of the fluid collection and surrounding vasculature thereby allowing precise and safe cyst-gastrostomy or cyst-duodenostomy creation. In this systematic review, only two [10, 22] out of seven studies used EUS exclusively. In this analysis, five patients died in the percutaneous group compared to zero in the endoscopic group, but this difference was not statistically significant. However, of note, the studies included in this meta-analysis are retrospective and only two studies [10, 11] adjusted for comorbidities in both groups.

The rate of re-intervention was found to be higher in the percutaneous group compared to the endoscopic group. This may be due to problems related to percutaneous drain positions and patency. PFCs tend to collapse with drainage of fluid which could cause drain dislodgment or displacement requiring repositioning. Furthermore, these are smaller caliber drains which tend to occlude necessitating a repeat procedure for drain exchange or upsizing. And lastly, percutaneous drains need to be flushed every day for successful drainage. Patients who are poorly compliant with such protocols are at increased risk of drain malfunction, dislodgment, and infection. The length of hospital stay was also found to be higher in the percutaneous group, which may be partially due to the increased rates of re-intervention and lower rates of clinical success. Although we could not perform a formal cost-effective analysis, as such data were not uniformly provided, the higher rates of re-interventions and longer hospital stays together may translate into higher costs associated with percutaneous drainage. Only one study [10] compared the costs and found that the endoscopic option was more cost effective.

This is the first meta-analysis to compare the efficacy and safety of endoscopic versus percutaneous drainage for the management of PFCs. We used a comprehensive search strategy and included all relevant studies. Our analyses may be weakened by inherent limitations of meta-analyses and of the included studies. All of the studies involved were observational studies. Our analysis of clinical success was initially limited by moderate heterogeneity, but with sensitivity analysis we were able to explain heterogeneity by excluding the study evaluating WON exclusively. Our results for clinical success remained consistent after such analysis. Considerable heterogeneity was also found in rates of re-intervention analysis, but due to limited data, this could not be well explored. However, all three studies showed consistently lower rates in the endoscopic group which is reassuring. We were unable to evaluate whether use of EUS resulted in a lower adverse events rate, or if type of stent influenced outcomes as such data were not provided.

Conclusions

This meta-analysis confirms that endoscopic drainage should be the preferred therapeutic modality for symptomatic PFCs compared to percutaneous drainage, as it is associated with significantly better clinical success, lower re-intervention rates, and shorter hospital length of stay. Additionally, with recent improvements in endoscopic techniques not included in this analysis, specifically the routine use of EUS and LAMS, these discrepancies could be expected to be even more pronounced than demonstrated in our study. Further study is needed.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Endoscopy Mean</th>
<th>Endoscopy SD</th>
<th>Endoscopy Total</th>
<th>Percutaneous Mean</th>
<th>Percutaneous SD</th>
<th>Percutaneous Total</th>
<th>Mean difference IV, Random, 95 % CI</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kumar 2014</td>
<td>1.4</td>
<td>0.2</td>
<td>12</td>
<td>2</td>
<td>0.2</td>
<td>12</td>
<td>44.7 % –0.60 [–0.76, –0.44]</td>
<td>2014</td>
</tr>
<tr>
<td>Keane, 2016</td>
<td>2.9</td>
<td>1.76</td>
<td>109</td>
<td>4.65</td>
<td>2.91</td>
<td>59</td>
<td>9.0 % –1.75 [–2.59, –0.91]</td>
<td>2016</td>
</tr>
<tr>
<td>Ngamruengphong, 2017</td>
<td>1</td>
<td>0.2</td>
<td>28</td>
<td>1.5</td>
<td>0.57</td>
<td>87</td>
<td>46.3 % –0.50 [–0.64, –0.36]</td>
<td>2017</td>
</tr>
<tr>
<td>Total (95 % CI)</td>
<td></td>
<td></td>
<td>149</td>
<td></td>
<td></td>
<td>154</td>
<td>100.0 % –0.66 [–0.93, –0.38]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.04; Chi² = 8.70, df = 2 (P = 0.01); I² = 77 %

Test for overall effect: Z = 4.66 (P < 0.00001)

Study or Subgroup | Endoscopy Mean | Endoscopy SD | Endoscopy Total | Percutaneous Mean | Percutaneous SD | Percutaneous Total | Mean difference IV, Random, 95 % CI | Year |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Azeem 2012</td>
<td>4.66</td>
<td>5.92</td>
<td>15</td>
<td>9.5</td>
<td>14.81</td>
<td>28</td>
<td>24.4 % –4.84 [–11.09, 1.41]</td>
<td>2012</td>
</tr>
<tr>
<td>Kumar, 2014</td>
<td>5.2</td>
<td>1.4</td>
<td>12</td>
<td>17</td>
<td>5.9</td>
<td>12</td>
<td>43.4 % –11.80 [–15.23, –8.37]</td>
<td>2014</td>
</tr>
<tr>
<td>Total (95 % CI)</td>
<td></td>
<td></td>
<td>68</td>
<td></td>
<td></td>
<td>80</td>
<td>100.0 % –8.97 [–12.88, –5.07]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 6.07; Chi² = 4.07, df = 2 (P = 0.13); I² = 51 %

Test for overall effect: Z = 4.51 (P < 0.00001)
Competing interests

Michel Kahaleh MD has received grant support from Boston Scientific, Fujinon, EMcision, Xlumen Inc., W. L. Gore, MaunaKea, Apollo Endosurgery, Cook Endoscopy, ASPIRE Bariatrics, Gl Dynamics, NinePoint Medical, Merit Medical, Olympus and MI Tech. He is a consultant for Boston Scientific, Xlumena Inc., Concordia Laboratories Inc, ABBvie, and MaunaKea Tech. All other authors have no conflicts of interest to report.

References

Appendix 1

PubMed search strategy

((((Pancreatic-fluid-collection* OR pancreatic fluid collection OR PFC OR walled-off- pancreatic-necros* OR WOPN OR pancreatic-abscess* OR peripancreatic-fluid-collection* OR ((Pancreas OR pancreatic OR intrapancreatic OR peripancreatic) AND (pancreatic pseudocyst* OR pseudocyst* OR walled-off- necros* OR WON OR necrotic-collection* OR cystic-collection* OR necrosis[mesh] OR cysts[mesh:no exp]) OR &quot;pancreatic pseudocyst&quot;[Mesh] OR necrosectomy OR drain OR drainage)))))) AND ((((endoscopic-ultrasonograph* OR endosonograph* OR EUS OR interventional-ultrasonograph* OR endoscopic-drainage* OR therapeutic-EUS* OR interventional-EUS* OR interventional-ultrasound* OR Intravascular-Ultrasound* OR Echo-Endoscopy OR eus-guided OR eus guided OR direct endoscopic OR transcutanous endoscopic OR Ultrasonic-Endoscopy* OR &quot;Ultrasoundography, Interventional&quot;[Mesh] OR &quot;Endosonography&quot;[Mesh] OR endoscopy, gastrointestinal[mesh] OR endoscopic ultrasound-guided fine needle aspiration [mesh] AND percutaneous))))}